Literature DB >> 15316134

Enhancing effect of dietary cholesterol and inhibitory effect of pravastatin on allergic pulmonary inflammation.

Ya-Fan Yeh1, Song-Lih Huang.   

Abstract

To elucidate the link between the intake of animal fat and asthma, a murine model was developed to examine the effect of dietary cholesterol on pulmonary allergic inflammation. Male C57BL6 mice were fed either a control diet or a diet supplemented with 2% cholesterol. Following sensitization and inhalation exposure to ovalbumin, the bronchoalveolar lavage fluid of mice in the cholesterol group contained higher numbers of eosinophils and elevated levels of IL-5, PGE(2), and MCP-1. In addition, dietary cholesterol also resulted in elevated production of IL-4 and IFN-gamma by lymphocytes isolated from the lungs. These inflammatory indicators were all significantly correlated with serum cholesterol levels. In contrast to the effect of dietary cholesterol, adding pravastatin to the drinking water significantly reduced eosinophil infiltration and the levels of IL-5, PGE(2) and MCP-1 in lavage fluid. Although dietary cholesterol did not alter baseline IL-12 in the lungs, in mice challenged with ovalbumin the IL-12 levels were reduced in the cholesterol group and elevated significantly in the pravastatin group. The results suggest that dietary cholesterol might enhance pulmonary allergic inflammation, possibly involving both nonspecific inflammatory processes and lymphocyte activities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316134     DOI: 10.1007/bf02256124

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  24 in total

Review 1.  Potential therapeutic role for statins in respiratory disease.

Authors:  E Hothersall; C McSharry; N C Thomson
Journal:  Thorax       Date:  2006-08       Impact factor: 9.139

2.  Revisiting "Good" and "Bad" Cholesterol. The Battle over Flow through Arteries Now Shifts to Flow through Airways.

Authors:  Michael B Fessler
Journal:  Am J Respir Crit Care Med       Date:  2015-05-01       Impact factor: 21.405

Review 3.  A New Frontier in Immunometabolism. Cholesterol in Lung Health and Disease.

Authors:  Michael B Fessler
Journal:  Ann Am Thorac Soc       Date:  2017-11

Review 4.  Regulation of Adaptive Immunity in Health and Disease by Cholesterol Metabolism.

Authors:  Michael B Fessler
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

5.  Emerging roles for cholesterol and lipoproteins in lung disease.

Authors:  Kymberly M Gowdy; Michael B Fessler
Journal:  Pulm Pharmacol Ther       Date:  2012-06-15       Impact factor: 3.410

Review 6.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

7.  Relationship of serum cholesterol levels to atopy in the US population.

Authors:  M B Fessler; R Jaramillo; P W Crockett; D C Zeldin
Journal:  Allergy       Date:  2009-12-16       Impact factor: 13.146

8.  Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond.

Authors:  Amir A Zeki; Lisa Franzi; Jerold Last; Nicholas J Kenyon
Journal:  Am J Respir Crit Care Med       Date:  2009-07-16       Impact factor: 21.405

Review 9.  Interleukin-17 regulation: an attractive therapeutic approach for asthma.

Authors:  Seoung Ju Park; Yong Chul Lee
Journal:  Respir Res       Date:  2010-06-16

10.  Lysophosphatidic acid and apolipoprotein A1 predict increased risk of developing World Trade Center-lung injury: a nested case-control study.

Authors:  Jun Tsukiji; Soo Jung Cho; Ghislaine C Echevarria; Sophia Kwon; Phillip Joseph; Edward J Schenck; Bushra Naveed; David J Prezant; William N Rom; Ann Marie Schmidt; Michael D Weiden; Anna Nolan
Journal:  Biomarkers       Date:  2014-02-19       Impact factor: 2.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.